)

Longboard Pharmaceuticals (LBPH) investor relations material
Longboard Pharmaceuticals Q3 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Entered into a definitive merger agreement with H. Lundbeck A/S for a $60/share cash acquisition, pending customary closing conditions and regulatory approvals.
Lead candidate bexicaserin (LP352) advanced to global Phase 3 for developmental and epileptic encephalopathies (DEEs) and Dravet syndrome, with FDA Breakthrough Therapy, Rare Pediatric Disease, and Orphan Drug designations.
EMA Paediatric Committee issued a positive opinion for bexicaserin's Paediatric Investigation Plan for children as young as 2.
LP659 completed Phase 1 SAD trial; proposed MAD study placed on full clinical hold by FDA, with options under evaluation.
Net loss increased year-over-year due to higher R&D and G&A expenses, including merger-related costs.
Financial highlights
Net loss for Q3 2024 was $24.5 million, up from $12.9 million in Q3 2023; net loss per share was $0.63 for Q3 2024.
Research and development expenses rose to $21.5 million in Q3 2024 (up 105% year-over-year).
General and administrative expenses increased to $6.7 million in Q3 2024 (up 116% year-over-year), including $0.7 million in merger-related costs.
Cash, cash equivalents, and short-term investments totaled $288.4 million as of September 30, 2024.
Interest income for Q3 2024 was $3.7 million, up from $0.7 million in Q3 2023.
Outlook and guidance
Existing cash, cash equivalents, and short-term investments expected to fund operations for at least the next 12 months.
No revenue expected until successful development and regulatory approval of product candidates, which is not anticipated for several years.
Ongoing Phase 3 DEEP SEA Study for bexicaserin in Dravet syndrome, with continued focus on advancing clinical programs.
During the merger process, capital raising and certain business activities are restricted.
Pending acquisition by Lundbeck subject to regulatory approvals and closing conditions.
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage